Aarti Drugs Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ywo4vpnkaj4gm3vopfdemrsm.pdf

Key Takeaways


Demand & Volume Recovery

Adhish Patil: "Whatever budget we are building in for the upcoming financial year, that is purely based on the volumes. In fact, we have factored in negative price growth."

Margin Trajectory & Profitability

Adhish Patil: "Typically it happens that in long term, the mean, in terms of percentage margins, the long-term mean, it comes back to that. So that is the reason, why we feel that once everything is stable, it is not moving for three months, four months, five months, then definitely we feel that our EBITDA margin should come back to 14% to 16%."

Capex Program & Capacity Expansion


Formulation Business Pivot


New Products & Competitive Position

Harit Shah: "Most of the products, we are competing with China, and we are able to compete them in the export markets. So, we are not unduly worried."

Regulatory & Shareholder Updates


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin14% to 16% range; improvement to begin in Q1 FY24FY24
Standalone bottom line25% to 35% jumpFY24
Volume growth (internal target)15% to 20%FY24
Value growthDouble-digit despite negative price variationFY24
Gross margin improvement2–3% improvement expectedQ1 FY24
Tarapur specialty chemical capexCompletedEnd-Q1 FY24
Tarapur dermatology GreenfieldCompletedEnd-Q2 FY24
Derma facility full capacity100% capacity onlineMarch/April 2024
Metformin expansion (small)~40% incremental capacityQ1 FY24
Metformin expansion (large)Toward 1,400–1,500 tonsEnd-FY24
Overall ₹600 crores capexAlmost entirely finished; only Sarigam anti-diabetic Brownfield remainsEnd-FY24
Spec-chem/intermediates utilization50% utilizationH2 FY24
API capacity utilizationCross 70%H2 FY25
API capacity full utilization100% onlineFY25
Formulation regulated-market approvalsMultiple products filed; approvals expectedNext 12–18 months
Formulation regulated-market revenueSignificant percent of salesNext 12 months
Baddi oncology facility revenueRevenue contribution beginsNext 12 months
New formulation launch revenue₹150–200 crores at full potentialOnce commercialized
EBITDA margin aspiration18%Next 3–4 years
Shareholder payout~25% of PAT; prior-year shortfall coveredFY24

Key Metrics

MetricQ4 FY23
Standalone revenue₹697.2 cr, ~9% YoY growth vs ₹642.1 cr
Standalone share of consolidated revenue~92%
Domestic revenue share (standalone)~62%, grew ~13% YoY
Export revenue share (standalone)~38%, grew ~7% YoY
Standalone EBITDA margin12.84%, up ~1.8 ppt QoQ from December quarter
FY24 EBITDA margin guidance14% to 16% for full year FY24
FY24 standalone bottom line growth aim25% to 35% jump YoY
API volume growth9% YoY for Q4; ~1.5% for full year FY23
API rate variance (Mar '23 vs Mar '22)Just below 2%, Q4 growth mostly volume-driven
Formulation segment revenue₹56.8 cr, ~8% of consolidated revenue
Ciprofloxacin contribution~15% to 20% of standalone API business
Top 10 products contributionMid-70s (standalone), early 70s (consolidated)
API therapeutic mix: antibiotic~45% of total API sales
API therapeutic mix: anti-diabetic~15% of total API sales
API therapeutic mix: anti-protozoal~16% of total API sales
API therapeutic mix: anti-inflammatory~13% of total API sales
API therapeutic mix: anti-fungal~8% of total API sales
Consolidated capex incurred (last 2 years)~₹315 cr, ~50% of ₹600 cr target
FY24 capex expected₹250 cr to ₹350 cr
Standalone revenue capacity (current)₹2,800 cr to ₹3,000 cr (ex-formulation)
Standalone revenue potential (post-capex)₹4,000 cr (ex-formulation)
Formulation revenue potential (post-capex)₹500 cr plus
Metformin current manufacturing1,000 to 1,050 tons, export-domestic split 50:50
Metformin capacity expansion40% increase in Q1 FY24, to 1,400-1,500 tons
Raw material inventory days reductionDown 10 days from end-December
Finished goods inventory days reductionDown ~8 days
FY24 expected rate variation decline8% to 10% decline
FY24 internal volume growth target15% to 20%
Q1 FY24 API selling price decline expected2.5% to 5% vs Q4 FY23
Gross margin improvement expectation2% to 3% improvement once stable
Aspirational EBITDA margin (3-4 years)18%
Shareholder payout policy~25% of PAT via buyback or dividend